ARCHIVES

Amgen Cancels Rilotumumab Trials in Gastric Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

A.D. Little Gets 42.4 Million Contract Award

May 2, 1975

House Committee Asks Varmus About Impact of Clinical Center construction On NIH Programs

April 26, 1996

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

April 25, 2014

Post-Hoc Analysis of ThermoDox Suggests OS Improvement

January 31, 2014

Dose Dense Chemotherapy Regimen Improves Survival In Breast Cancer

December 27, 2002

Pepper Committee, Impressed By Progress Reports, Promises Help With NCI Funding

June 29, 1979